Consensus on the clinical utility of digital mobility outcomes for personalized clinical decision support in parkinson's disease
Background
Methods
Results
Conclusions
Digital mobility outcomes (DMOs) are emerging biomarkers that provide objective, quantitative, and examiner-independent measures for clinical studies. However, their clinical utility in Parkinson’s disease (PD), including benefits for diagnosis, decision-making, or health outcomes compared with standard care, has not been systematically addressed. This study aimed to develop a structured conceptual framework linking DMO-derived knowledge to clinical domains in PD.
A three-round consensus-building study was conducted with 12 experts from the Mobilise-D Parkinson’s Disease Working Group. Experts designed and ranked framework components using 5-point Likert scales. Consensus required high agreement and low disagreement. Secondary objectives included evaluating timelines for clinical applicability, implementation challenges, and the role of DMOs in clinical decision-making.
Full consensus was achieved after three rounds. The final framework comprised three categories—Disease Diagnosis, Patient Evaluation, and Treatment Evaluation—and six domains: enhancing diagnostic procedures, risk prediction, early detection of deterioration, enhanced clinical judgment, treatment selection, and monitoring treatment response. Experts anticipated that DMOs will meaningfully support clinical decision-making within 1–5 years. The primary challenge identified was the lack of clear reference values to support DMO interpretability.
This framework provides a foundation for future studies, broader expert engagement, and extension beyond PD. It also supports the integration of DMOs into clinical trials and represents an initial step toward guidelines for assessing clinical utility and enabling real-world clinical implementation.
Preview
Rights
Use and reproduction:
Please note that individual components of the publication may be subject to other licensing or copyright conditions.